Sort   by:  
 Page size 
UnknownApplication of Radiomics in Melanoma: A Systematic Review and Meta-Analysis.
Not available
S-EPMC12524276 | biostudies-literature
Unknown"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Not available
S-EPMC2972284 | biostudies-literature
UnknownIdentification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.
Not available
S-EPMC10940473 | biostudies-literature
UnknownCirculating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy.
Not available
S-EPMC11325673 | biostudies-literature
UnknownHematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
Not available
S-EPMC12816168 | biostudies-literature
UnknownReduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Not available
S-EPMC7544958 | biostudies-literature
UnknownVitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Not available
S-EPMC8971439 | biostudies-literature
UnknownBaseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
Not available
S-EPMC4580390 | biostudies-literature
UnknownPrimary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Not available
S-EPMC10814710 | biostudies-literature
UnknownCase report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.
Not available
S-EPMC11324500 | biostudies-literature
Sort   by:  
 Page size